Loren Data's SAM Daily™

FBO DAILY ISSUE OF APRIL 03, 2004 FBO #0859
SOLICITATION NOTICE

B -- Developemnt of Data Collection Manuals, Follow-up of the Stavanger Nested Case-Control Study of Preeclampsia

Notice Date

4/1/2004
 

Notice Type

Solicitation Notice
 

NAICS

541710 — Research and Development in the Physical, Engineering, and Life Sciences
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-40053-NG
 

Response Due

4/16/2004
 

Archive Date

5/1/2004
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
 

E-Mail Address

holdcram@exchange.nih.gov, rs442i@nih.gov
 

Description

The National Cancer Institute (NCI), Basic Research Laboratory (BRL), Center for Cancer Research (CCR) plans to procure on a sole sourece basis, Development of data collection manuals, the invitation and clinical follow-up of the 1993 birth cohort to the Stavanger Nested Case-Control Study of Preeclampsia with the Rogaland Central Hospital, PO Box 8100, NO-4068 Stavanger, Norway. The acquisition is being conducted under the simplified acquisition procedures authorized in FAR Part 13. The North American Industry Classification System Code is 541710 and the business size standard is 500 employees. Background: The Basic Research Laboratory, Center for Cancer Research, NCI, requires the development of manuals of operation for the conduct of a prospective study of puberty in and the initiation of the first three months of the prospective study in the 1993 birth cohort members and their parents to the study known as: The influence of preeclampsia on hormonal and anthropometric status in boys and girls at 10 and 13 years of age: Follow-up of the Stavanger population-based nested case-control study (heretofore referred to as the Puberty Follow-Up Study). The Puberty Follow-Up Study has a high-risk population of mothers and children participated in a birth study when the mothers suffered from preeclampsia during the index pregnancy in comparison with an age-matched set of normotensive controls (mothers and their offspring). The ultimate purpose of this research project is to explore the biological mechanisms underlying why women who suffered from preeclampsia during pregnancy and their offspring are at significantly reduced risk of breast cancer (in mothers and daughters of that pregnancy) while the male offspring are at the lowest risk of prostate cancer identified in the literature. The information collected during the pretest and pilot enabled the investigators at NCI, in collaboration with the Norwegian University of Science and Technology and The Rogaland Hospital, Stavanger, Norway to develop a follow-up of the cohort with the ultimate goal of identifying hormonal and other mechanisms associated with the lowered cancer risk in this population. They have conducted the only population-based study of women diagnosed with preeclampsia in pregnancy and their offspring and a comparable set of normotensive controls. The birth study utilized data from the birth registry in Norway and stored cord bloods to demonstrate hormonal and anthropometric differences in the offspring of the preeclamptic and normotensive mothers. The NCI has the opportunity to conduct a follow-up of these mothers and children, linking with the original study database. The questionnaire items focus on dietary intake during the index pregnancy and since the birth of the index child, lifestyle and demographic characteristics, family history of cancer, and family history of reproductive disease, including preeclampsia in the mother's and biological father's families. The manuals of operation will provide the guidelines for questionnaire reported data, blood and clinical evaluations on the children as the cohorts are followed. It is NCI's intent to utilize the study manuals of operation in the conduct of the first three months of the clinical study follow-up of the members born in 1993 as the offspring enter puberty and adolescence, when hormonal and other growth factors might differ appreciably from children of normotensive pregnancies. Period of Performance: May 1, 2004 through August 30, 2004. Rogaland Central Hospital is the only known source that can provide the aforementioned requirements. The Rogaland Hospital has as its director, the original Principal Investigator to the Stavanger Nested Case-Control Study of Preeclampsia, who has had direct contact with all the families involved in the original study, thereby having credibility and links to the study population of interest. The training in obstetrics and gynecology along with the experience of the Pediatric Department in adolescent medicine has given the team the knowledge and background to develop the manuals of operation. Therefore the background of the population, nature of its low risk for cancer, as well as the expertise and educational background of the original principal investigator and his team are all reasons for the sole source justification. This notice of intent is not a request for competitive quotation. However, if any interested party believes it can meet the above requirements, it may submit a statement of capabilities. The capability statement and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can fully meet the requirements herein. Capability statements must be received in the contracting office by 1:00 PM EST on April 16, 2004. If you have any questions, please submit them in writing via electronic mail to Malinda Holdcraft, Purchasing Agent on holdcram@exchange.nih.gov or by fax 301-402-4513. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. NCI-40053-NG.
 

Place of Performance

Address: NCI

Zip Code: 20892

Country: USA
 

Record

SN00558142-W 20040403/040401211831 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |